Macro- and micronutrients in African-Americans with heart failure

Heart Failure Reviews

Volumn 11, Issue 1, 2006, Pages 45-55

  Bhattacharya, Syamal K ^a   Ahokas, Robert A ^a   Carbone, Laura D ^a,b   Newman, Kevin P ^a   Gerling, Ivan C ^a,b   Sun, Yao ^a   Weber, Karl T ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Calcium; Hypovitaminosis D; Magnesium; Secondary hyperparathyroidism; Selenium; Zinc

Indexed keywords

25 HYDROXYVITAMIN D; ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIOXIDANT; CALCITRIOL; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; COLECALCIFEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; LOOP DIURETIC AGENT; MAGNESIUM; SELENIUM; SPIRONOLACTONE; TRACE ELEMENT; VITAMIN D; ZINC; ZOFENOPRIL;

AFRICAN AMERICAN; ARTICLE; BONE DENSITY; CALCIUM BALANCE; CARDIOMYOPATHY; CELLULAR IMMUNITY; CONGESTIVE HEART FAILURE; DIET SUPPLEMENTATION; DIET THERAPY; DIETARY INTAKE; DISEASE SEVERITY; DOSE RESPONSE; DRUG MEGADOSE; DYSGEUSIA; HUMAN; HUMORAL IMMUNITY; HYPERALDOSTERONISM; HYPERCALCEMIA; HYPERTHYROIDISM; LIFESTYLE; MACRONUTRIENT; NONHUMAN; OSTEOPENIA; OSTEOPOROSIS; OXIDATIVE STRESS; PARATHYROIDECTOMY; PLASMA RENIN ACTIVITY; POSTMENOPAUSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SELENIUM DEFICIENCY; SODIUM RETENTION; SUN EXPOSURE; VITAMIN D DEFICIENCY; WATER RETENTION; ZINC DEFICIENCY;

AFRICAN AMERICANS; ANIMALS; CALCIUM; CYTOKINES; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERALDOSTERONISM; IMMUNITY, CELLULAR; MICRONUTRIENTS; NUTRITIONAL STATUS; OXIDATIVE STRESS; PARATHYROID HORMONE; SELENIUM; VITAMIN D; ZINC;

EID: 33745617699     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-006-9192-6     Document Type: Article

References (146)

1. Alexander M, Grumbach K, Selby J, Brown AF, Washington E. Hospitalization for congestive heart failure. Explaining racial differences. JAMA 1995;274:1037-42.
2. Philbin EF, DiSalvo TG. Influence of race and gender on care process, resource use, and hospital-based outcomes in congestive heart failure. Am J Cardiol 1998;82:76-81.
3. Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999;340:609-16.
4. Ofili EO, Mayberry R, Alema-Mensah E, Saleem S, Hamirani K, Jones C, et al. Gender differences and practice implications of risk factors for frequent hospitalization for heart failure in an urban center serving predominantly African-American patients. Am J Cardiol 1999;83:1350-5.
5. Vaccarino V, Chen YT, Wang Y, Radford MJ, Krumholz HM. Sex differences in the clinical care and outcomes of congestive heart failure in the elderly. Am Heart J 1999;138 (5 Pt 1):835-42.
6. Lafata JE, Pladevall M, Divine G, Ayoub M, Philbin EF. Are there race/ ethnicity differences in outpatient congestive heart failure management, hospital use, and mortality among an insured population? Med Care 2004;42:680-9.
7. Yancy CW. Heart failure in African Americans. Am J Cardiol 2005;96 Suppl 7B:3I-12i.
8. Thomas KL, East MA, Velazquez EJ, Tuttle RH, Shaw LK, O'Connor CM, et al. Outcomes by race and etiology of patients with left ventricular systolic dysfunction. Am J Cardiol 2005;96:956-63.
9. Bell NH, Greene A, Epstein S, Oexmann MJ, Shaw S, Shary J. Evidence for alteration of the vitamin D-endocrine system in blacks. J Clin Invest 1985;76:470-3.
10. Sawaya BP, Monier-Faugere MC, Ratanapanichkich P, Butros R, Wedlund PJ, Fanti P. Racial differences in parathyroid hormone levels in patients with secondary hyperparathyroidism. Clin Nephrol 2002;57:51-5.
11. Gupta A, Kallenbach LR, Zasuwa G, Divine GW. Race is a major determinant of secondary hyperparathyroidism in uremic patients. J Am Soc Nephrol 2000;11:330-4.
12. Perry HM, 3rd, Miller DK, Morley JE, Horowitz M, Kaiser FE, Perry HM, Jr., et al. A preliminary report of vitamin D and calcium metabolism in older African Americans. J Am Geriatr Soc 1993;41:612-6.
13. Fuleihan GE, Gundberg CM, Gleason R, Brown EM, Stromski ME, Grant FD, et al. Racial differences in parathyroid hormone dynamics. J Clin Endocrinol Metab 1994;79:1642-7.
14. Harris SS, Soteriades E, Coolidge JA, Mudgal S, Dawson-Hughes B. Vitamin D insufficiency and hyperparathyroidism in a low income, multiracial, elderly population. J Clin Endocrinol Metab 2000;85:4125-30.
15. Bikle DD, Ettinger B, Sidney S, Tekawa IS, Tolan K. Differences in calcium metabolism between black and white men and women. Miner Electrolyte Metab 1999;25:178-84.
16. Khouzam RN, Dishmon DA, Farah V, Flax SD, Carbone LD, Weber KT., Secondary hyperparathyroidism in patients with untreated and treated congestive heart failure. Am J Med Sci 2006;331:30-4.
17. LaGuardia SP, Dockery BK, Bhattacharya SK, Nelson MD, Carbone LD, Weber KT. Secondary hyperparathyroidism and hypovitaminosis D in African-Americans with decompensated heart failure. Am J Med Sci 2006 (In press).
18. Holick MF. McCollum Award Lecture, 1994: Vitamin D-new horizons for the 21st century. Am J Clin Nutr 1994;60:619-30.
19. Cosman F, Nieves J, Morgan D, Shen V, Sherwood D, Parisien M, et al. Parathyroid hormone secretory response to EDTA-induced hypocalcemia in black and white premenopausal women. Calcif Tissue Int 1999;65:257-61.
20. Horl WH. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant 2004;19 Suppl 5:V2-V8.
21. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, et al. Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol 2004;287:H2023-H6.
22. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, et al. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation 2005;111:871-8.
23. Rastegar A, Agus Z, Connor TB, Goldberg M. Renal handling of calcium and phosphate during mineralocorticoid "escape" in man. Kidney Int 1972;2:279-86.
24. Cappuccio FP, Kalaitzidis R, Duneclift S, Eastwood JB. Unravelling the links between calcium excretion, salt intake, hypertension, kidney stones and bone metabolism. J Nephrol 2000;13:169-77.
25. Resnick LM, Laragh JH. Calcium metabolism and parathyroid function in primary aldosteronism. Am J Med 1985;78:385-90.
26. Rossi E, Sani C, Perazzoli F, Casoli MC, Negro A, Dotti C. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens 1995;8:884-93.
27. Mason RP, Kalinowski L, Jacob RF, Jacoby AM, Malinski T. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 2005;112:3795-801.
28. Massry SG, Smogorzewski M. Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol 1994;14:219-31.
29. Vidal A, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC, Weber KT. The calcium paradox of aldosteronism and the role of the parathyroid glands. Am J Physiol Heart Circ Physiol 2006;290:H286-H94.
30. Zive MM, Nicklas TA, Busch EC, Myers L, Berenson GS. Marginal vitamin and mineral intakes of young adults: The Bogalusa Heart Study. J Adolesc Health 1996;19:39-47.
31. Ranganathan R, Nicklas TA, Yang SJ, Berenson GS. The nutritional impact of dairy product consumption on dietary intakes of adults (1995-1996): the Bogalusa Heart Study. J Am Diet Assoc 2005;105:1391-400.
32. Bell RA, Vitolins MZ, Arcury TA, Quandt SA. Food consumption patterns of rural older African American, Native American, and white adults in North Carolina. J Nutr Elder 2003;23:1-16.
33. Lewis SM, Mayhugh MA, Freni SC, Thorn B, Cardoso S, Buffington C, et al. Assessment of antioxidant nutrient intake of a population of southern US African-American and Caucasian women of various ages when compared to dietary reference intakes. J Nutr Health Aging 2003;7:121-8.
34. Ervin RB, Kennedy-Stephenson J. Mineral intakes of elderly adult supplement and non-supplement users in the third national health and nutrition examination survey. J Nutr 2002;132:3422-7.
35. Neggers YH, Bindon JR, Dressler WW. The relationship between zinc and copper status and lipid levels in African-Americans. Biol Trace Elem Res 2001;79:1-13.
36. Neggers YH, Goldenberg RL, Cliver SP, Copper RL. Determinants of zinc intake in low-income black and white pregnant women. Biol Trace Elem Res 1998;64:221-8.
37. Vitolins MZ, Quandt SA, Case LD, Bell RA, Arcury TA, McDonald J. Vitamin and mineral supplement use by older rural adults. J Gerontol A Biol Sci Med Sci 2000;55:M613-M7.
38. Rishi I, Baidouri H, Abbasi JA, Bullard-Dillard R, Kajdacsy-Balla A, Pestaner JP, et al. Prostate cancer in African American men is associated with downregulation of zinc transporters. Appl Immunohistochem Mol Morphol 2003;11:253-60.
39. Arroyo M, LaGuardia SP, Bhattacharya SK, Nelson MD, Johnson PL, Carbone LD, et al. Micronutrients in African-Americans with decompensated and compensated heart failure. J Lab Clin Med 2006 (In press).
40. Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC. Edema of cardiac origin: Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 1989;80:299-305.
41. Villarreal D, Freeman RH, Johnson RA. Neurohormonal modulators and sodium balance in experimental heart failure. Am J Physiol 1993;264:H1187-H93.
42. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990;82:1730-6.
43. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang C, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heartfailure: A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-9.
44. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-97.
45. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348:2007-18.
46. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
47. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
48. Cesselli D, Jakoniuk I, Barlucchi L, Beltrami AP, Hintze TH, Nadal-Ginard B, et al. Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res 2001;89:279-86.
49. Sam F, Kerstetter DL, Pimental DR, Mulukutla S, Tabaee A, Bristow MR, et al. Increased reactive oxygen species production and functional alterations in antioxidant enzymes in human failing myocardium. J Card Fail 2005;11:473-80.
50. Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998;31:1352-6.
51. Miyamoto M, Kishimoto C, Shioji K, Lee JD, Shimizu H, Ueda T, et al. Cutaneous arteriolar thioredoxin expression in patients with heart failure. Circ J 2003;67:116-8.
52. Tsutsui H, Ide T, Hayashidani S, Suematsu N, Shiomi T, Wen J, et al. Enhanced generation of reactive oxygen species in the limb skeletal muscles from a murine infarct model of heart failure. Circulation 2001;104:134-6.
53. Ahokas RA, Warrington KJ, Gerling IC, Sun Y, Wodi LA, Herring PA, et al. Aldosteronism and peripheral blood mononuclear cell activation. A neuroendocrine-immune interface. Circ Res 2003;93:e124-e35.
54. 2 in peripheral blood mononuclear cells. Circulation 2005;111:51-7.
55. Gerling IC, Sun Y, Ahokas RA, Wodi LA, Bhattacharya SK, Warrington KJ, et al. Aldosteronism: An immunostimulatory state precedes the proinflammatory/fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol 2003;285:H813-H21.
56. Aukrust P, Ueland T, Müller F, Andreassen AK, Nordøy I, Aas H, et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998;97:1136-43.
57. Damras JK, Gullestad L, Ueland T, Solum NO, Simonsen S, Frøland SS, et al. CXC-chemokines, a new group of cytokines in congestive heart failure-possible role of platelets and monocytes. Cardiovasc Res 2000;45:428-36.
58. Damras JK, Gullestad L, Aass H, Simonsen S, Fjeld JG, Wikeby L, et al. Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure-modulatory effect of intravenous immunoglobulin. J Am Coll Cardiol 2001;38:187-93.
59. Yndestad A, Damras JK, Eiken HG, Holm T, Haug T, Simonsen S, et al. Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. Cardiovasc Res 2002;54:175-82.
60. Yndestad A, Holm AM, Müller: F, Simonsen S, Frøland SS, Gullestad L, et al. Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc Res 2003;60:141-6.
61. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart. Role of oxidative stress. Am J Pathol 2002;161:1773-81.
62. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997;96:526-34.
63. Anker SD, Clark AL, Teixeira MM, Hellewell PG, Coats AJ. Loss of bone mineral in patients with cachexia due to chronic heart failure. Am J Cardiol 1999;83:612-5.
64. Lee AH, Mull RL, Keenan GF, Callegari PE, Dalinka MK, Eisen HJ, et al. Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med 1994;96:35-41.
65. Shane E, Mancini D, Aaronson K, Silverberg SJ, Seibel MJ, Addesso V, et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med 1997;103:197-207.
66. Aquilani R, Opasich C, Verri M, Boschi F, Febo O, Pasini E, et al. Is nutritional intake adequate in chronic heart failure patients? J Am Coll Cardiol 2003;42:1218-23.
67. Silver MA. Dietary research in heart failure: Beyond the salt shaker. J Am Coll Cardiol 2003;42:1224-5.
68. Molavi B, Mehta JL. Oxidative stress in cardiovascular disease: molecular basis of its deleterious effects, its detection, and therapeutic considerations. Curr Opin Cardiol 2004;19:488-93.
69. Ungvari Z, Gupte SA, Recchia FA, Batkai S, Pacher P. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol 2005;3:221-9.
70. Wykretowicz A, Furmaniuk J, Smielecki J, Deskur-Smielecka E, Szczepanik A, Banaszak A, et al. The oxygen stress index and levels of circulating interleukin-10 and interleukin-6 in patients with chronic heart failure. Int J Cardiol 2004;94:283-7.
71. Shioji K, Nakamura H, Masutani H, Yodoi J. Redox regulation by thioredoxin in cardiovascular diseases. Antioxid Redox Signal 2003;5:795-802.
72. Takano H, Zou Y, Hasegawa H, Akazawa H, Nagai T, Komuro I. Oxidative stress-induced signal transduction pathways in cardiac myocytes: involvement of ROS in heart diseases. Antioxid Redox Signal 2003;5:789-94.
73. Demirbag R, Yilmaz R, Erel O, Gultekin U, Asci D, Elbasan Z. The relationship between potency of oxidative stress and severity of dilated cardiomyopathy. Can J Cardiol 2005;21:851-5.
74. Itoh M, Oh-Ishi S, Hatao H, Leeuwenburgh C, Selman C, Ohno H, et al. Effects of dietary calcium restriction and acute exercise on the antioxidant enzyme system and oxidative stress in rat diaphragm. Am J Physiol Regul Integr Comp Physiol 2004;287:R33-R8.
75. Dhalla AK, Singal PK. Antioxidant changes in hypertrophied and failing guinea pig hearts. Am J Physiol 1994;266 (4 Pt 2):H1280-H5.
76. Thakur S, Gupta N, Kakkar P. Serum copper and zinc concentrations and their relation to superoxide dismutase in severe malnutrition. Eur J Pediatr 2004;163:742-4.
77. Xia YM, Hill KE, Burk RF. Biochemical studies of a selenium-deficient population in China: Measurement of selenium, glutathione peroxidase and other oxidant defense indices in blood. J Nutr 1989;119:1318-26.
78. Thomas M, Vidal A, Bhattacharya SK, Ahokas RA, Johnson PL, Sun Y, et al. Hypozincemia and oxidative stress in rats with chronic aldosteronism. [abstr] J Investig Med 2006;54 Suppl 1:S264.
79. Latman NS, Sorensen JR, Kishore V. Effect of aldosterone on the serum zinc, copper, and magnesium concentrations in the rat. Horm Res 1984;20:192-6.
80. Malette LE, Henkin RI. Altered copper and zinc metabolism in primary hyperparathyroidism. Am J Med Sci 1976;272:167-74.
81. Chen SM, Kuo CD, Liao JF, Ho LT. Effects of parathyroid hormone on plasma zinc concentration in rat with chronic renal failure. Chin J Physiol 2005;48:121-8.
82. Zumkley H, Bertram HP, Vetter H, Zidek W, Losse H. Zinc metabolism during captopril treatment. Horm Metab Res 1985;17:256-8.
83. Koren-Michowitz M, Dishy V, Zaidenstein R, Yona O, Berman S, Weissgarten J, et al. The effect of losartan and losartan/hydrochlorothiazide fixed-combination on magnesium, zinc, and nitric oxide metabolism in hypertensive patients: A prospective open-label study. Am J Hypertens 2005;18:358-63.
84. Wester PO. Urinary zinc excretion during treatment with different diuretics. Acta Med Scand 1980;208:209-12.
85. Cohanim M, Yendt ER. The effects of thiazides on serum and urinary zinc in patients with renal calculi. Johns Hopkins Med J 1975;136:137-41.
86. Abu-Hamdan DK, Desai H, Sondheimer J, Felicetta J, Mahajan S, McDonald F. Taste acuity and zinc metabolism in captopril-treated hypertensive male patients. Am J Hypertens 1988;1 (3 Pt 3):303S-8S.
87. Kotsaki-Kovatsi VP, Koehler-Samouilidis G, Kovatsis A, Rozos G. Fluctuation of zinc, copper, magnesium and calcium concentrations in guinea pig tissues after administration of captopril (SQ 14225). J Trace Elem Med Biol 1997;11:32-6.
88. Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension: Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 1991;69:107-15.
89. Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 2003;42:49-55.
90. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002;40:504-10.
91. Goodwin KD, Ahokas RA, Bhattacharya SK, Sun Y, Gerling IC, Weber KT. Preventing oxidative stress in rats with aldosteronism by calcitriol and dietary calcium and magnesium supplements. Am J Med Sci 2006 (In press).
92. Horton R, Biglieri EG. Effect of aldosterone on the metabolism of magnesium. J Clin Endocrinol Metab 1962;22:1187-92.
93. Gehr MK, Goldberg M. Hypercalciuria of mineralocorticoid escape: clearance and micropuncture studies in the rat. Am J Physiol 1986;251 (5 Pt 2):F879-F88.
94. Stefenelli T, Pacher R, Woloszczuk W, Glogar D, Kaindl F. Parathyroid hormone and calcium behavior in advanced congestive heart failure [German]. Z Kardiol 1992;81:121-5.
95. Christ E, Linka A, Junga G, Odermatt M, Steinert H, Kiowski W, et al. Bone density and laboratory parameters of bone metabolism in patients with terminal heart disease [German]. Schweiz Med Wochenschr 1996;126:1553-9.
96. Schmid C, Kiowski W. Hyperparathyroidism in congestive heart failure. Am J Med 1998;104:508-9.
97. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P. Low vitamin D status: A contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 2003;41:105-12.
98. Rejnmark L, Vestergaard P, Heickendorff L, Andreasen F, Mosekilde L. Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: Results from a randomized controlled study with bumetanide. J Bone Miner Res 2006;21:163-70.
99. Ooms ME, Lips P, Van Lingen A, Valkenburg HA. Determinants of bone mineral density and risk factors for osteoporosis in healthy elderly women. J Bone Miner Res 1993;8:669-75.
100. Stein MS, Scherer SC, Walton SL, Gilbert RE, Ebeling PR, Flicker L, et al. Risk factors for secondary hyperparathyroidism in a nursing home population. Clin Endocrinol (Oxf) 1996;44:375-83.
101. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: A negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 2004;89-90:387-92.
102. Seligmann H, Halkin H, Rauchfleisch S, Kaufmann N, Motro M, Vered Z, et al. Thiamine deficiency in patients with congestive heart failure receiving long-term furosemide therapy: A pilot study. Am J Med 1991;91:151-5.
103. Dunn MA, Cousins RJ. Kinetics of zinc metabolism in the rat: Effect of dibutyryl cAMP. Am J Physiol 1989;256:E420-E30.
104. Lowe NM, Bremner I, Jackson MJ. Plasma 65 Zn kinetics in the rat. Br J Nutr 1991;65:445-55.
105. House WA, Wastney ME. Compartmental analysis of zinc kinetics in mature male rats. Am J Physiol 1997;273:R1117-R25.
106. Pfaffl MW, Windisch W. Influence of zinc deficiency on the mRNA expression of zinc transporters in adult rats. J Trace Elem Med Biol 2003;17:97-106.
107. Pfaffl MW, Gerstmayer B, Bosio A, Windisch W. Effect of zinc deficiency on the mRNA expression pattern in liver and jejunum of adult rats: monitoring gene expression using cDNA microarrays combined with real-time RT-PCR. J Nutr Biochem 2003;14:691-702.
108. Cousins RJ, Blanchard RK, Moore JB, Cui L, Green CL, Liuzzi JP, et al. Regulation of zinc metabolism and genomic outcomes. J Nutr 2003;133 (5 Suppl 1):1521S-6S.
109. King JC. Assessment of zinc status. J Nutr 1990;120 Suppl 11:1474-9.
110. Bales CW, DiSilvestro RA, Currie KL, Plaisted CS, Joung H, Galanos AN, et al. Marginal zinc deficiency in older adults: Responsiveness of zinc status indicators. J Am Coll Nutr 1994;13:455-62.
111. Borghesi LA, Lynes MA. Stress proteins as agents of immunological change: Some lessons from metallothionein. Cell Stress Chaperones 1996;1:99-108.
112. Ding HQ, Zhou BJ, Liu L, Cheng S. Oxidative stress and metallothionein expression in the liver of rats with severe thermal injury. Burns 2002;28:215-21.
113. Liu J, Squibb KS, Akkerman M, Nordberg GF, Lipsky M, Fowler BA. Cytotoxicity, zinc protection, and stress protein induction in rat proximal tubule cells exposed to cadmium chloride in primary cell culture. Ren Fail 1996;18:867-82.
114. Klosterhalfen B, Tons C, Hauptmann S, Tietze L, Offner FA, Kupper W, et al. Influence of heat shock protein 70 and metallothionein induction by zinc-bis-(DL-hydrogenaspartate) on the release of inflammatory mediators in a porcine model of recurrent endotoxemia. Biochem Pharmacol 1996;52:1201-10.
115. Ebadi M, Leuschen MP, el Refaey H, Hamada FM, Rojas P. The antioxidant properties of zinc and metallothionein. Neurochem Int 1996;29:159-66.
116. Prabhu KS, Zamamiri-Davis F, Stewart JB, Thompson JT, Sordillo LM, Reddy CC. Selenium deficiency increases the expression of inducible nitric oxide synthase in RAW 264.7 macrophages: Role of nuclear factor-kappaB in up-regulation. Biochem J 2002;366 (Pt 1):203-9.
117. Reddi AS, Bollineni JS. Selenium-deficient diet induces renal oxidative stress and injury via TGF-beta1 in normal and diabetic rats. Kidney Int 2001;59:1342-53.
118. Moreno-Reyes R, Egrise D, Neve J, Pasteels JL, Schoutens A. Selenium deficiency-induced growth retardation is associated with an impaired bone metabolism and osteopenia. J Bone Miner Res 2001;16:1556-63.
119. Venardos K, Harrison G, Headrick J, Perkins A. Effects of dietary selenium on glutathione peroxidase and thioredoxin reductase activity and recovery from cardiac ischemia-reperfusion. J Trace Elem Med Biol 2004;18:81-8.
120. Wu Q, Huang K, Xu H. Effects of long-term selenium deficiency on glutathione peroxidase and thioredoxin reductase activities and expressions in rat aorta. J Inorg Biochem 2003;94:301-6.
121. Wu Q, Huang K. Effect of long-term Se deficiency on the antioxidant capacities of rat vascular tissue. Biol Trace Elem Res 2004;98:73-84.
122. Faure P, Ramon O, Favier A, Halimi S. Selenium supplementation decreases nuclear factor-kappa B activity in peripheral blood mononuclear cells from type 2 diabetic patients. Eur J Clin Invest 2004;34:475-81.
123. Quercia RA, Korn S, O'Neill D, Dougherty JE, Ludwig M, Schweizer R, et al. Selenium deficiency and fatal cardiomyopathy in a patient receiving long-term home parenteral nutrition. Clin Pharm 1984;3:531-5.
124. Hatanaka N, Nakaden H, Yamamoto Y, Matsuo S, Fujikawa T, Matsusue S. Selenium kinetics and changes in glutathione peroxidase activities in patients receiving long-term parenteral nutrition and effects of supplementation with selenite. Nutrition 2000;16:22-6.
125. Weiss SL, Evenson JK, Thompson KM, Sunde RA. The selenium requirement for glutathione peroxidase mRNA level is half of the selenium requirement for glutathione peroxidase activity in female rats. J Nutr 1996;126:2260-7.
126. Kidd P. Th1/Th2 balance: The hypothesis, its limitations, and implications for health and disease. Altern Med Rev 2003;8:223-46.
127. Bao B, Prasad AS, Beck FW, Godmere M. Zinc modulates mRNA levels of cytokines. Am J Physiol Endocrinol Metab 2003;285:E1095-E102.
128. Santos-Neto L, Tosta CE, Dorea JG. Zinc reverses the increased sensitivity of lymphocytes from aged subjects to the antiproliferative effect of prostaglandin E2. Clin Immunol Immunopathol 1992;64:184-7.
129. Lesourd BM. Nutrition and immunity in the elderly: Modification of immune responses with nutritional treatments. Am J Clin Nutr 1997;66:478S-84S.
130. Klecha AJ, Salgueiro J, Wald M, Boccio J, Zubillaga M, Leonardi NM, et al. In vivo iron and zinc deficiency diminished T- and B-selective mitogen stimulation of murine lymphoid cells through protein kinase C-mediated mechanism. Biol Trace Elem Res 2005;104:173-83.
131. Ferencik M, Ebringer L. Modulatory effects of selenium and zinc on the immune system. Folia Microbiol (Praha) 2003;48:417-26.
132. van Rij AM, Thomson CD, McKenzie JM, Robinson MF. Selenium deficiency in total parenteral nutrition. Am J Clin Nutr 1979;32:2076-85.
133. Reeves WC, Marcuard SP, Willis SE, Movahed A. Reversible cardiomyopathy due to selenium deficiency. JPEN J Parenter Enteral Nutr 1989;13:663-5.
134. Sullivan JF, Blotcky AJ, Jetton MM, Hahn HK, Burch RE. Serum levels of selenium, calcium, copper magnesium, manganese and zinc in various human diseases. J Nutr 1979;109:1432-7.
135. Koch J, Neal EA, Schlott MJ, Garcia-Shelton YL, Chan MF, Weaver KE, et al. Zinc levels and infections in hospitalized patients with AIDS. Nutrition 1996;12:515-8.
136. van Lettow M, Harries AD, Kumwenda JJ, Zijlstra EE, Clark TD, Taha TE, et al. Micronutrient malnutrition and wasting in adults with pulmonary tuberculosis with and without HIV co-infection in Malawi. BMC Infect Dis 2004;4:61.
137. Dworkin BM, Rosenthal WS, Wormser GP, Weiss L, Nunez M, Joline C, et al. Abnormalities of blood selenium and glutathione peroxidase activity in patients with acquired immunodeficiency syndrome and aids-related complex. Biol Trace Elem Res 1988;15:167-77.
138. Kavanaugh-McHugh AL, Ruff A, Perlman E, Hutton N, Modlin J, Rowe S. Selenium deficiency and cardiomyopathy in acquired immunodeficiency syndrome. JPEN J Parenter Enteral Nutr 1991;15:347-9.
139. Vijaya J, Subramanyam G, Sukhaveni V, Abdul Latheef SA, Gupta SR, Sadhasivaiah G, et al. Selenium levels in dilated cardiomyopathy. J Indian Med Assoc 2000;98:166-9.
140. Ripa S, Ripa R, Giustiniani S. Are failured cardiomyopathies a zinc-deficit related disease? A study on Zn and Cu in patients with chronic failured dilated and hypertrophic cardiomyopathies. Minerva Med 1998;89:397-403.
141. Oster O. Trace element concentrations (Cu, Zn, Fe) in sera from patients with dilated cardiomyopathy. Clin Chim Acta 1993;214:209-18.
142. Golik A, Modai D, Averbukh Z, Sheffy M, Shamis A, Cohen N, et al. Zinc metabolism in patients treated with captopril versus enalapril. Metabolism 1990;39:665-7.
143. Golik A, Zaidenstein R, Dishi V, Blatt A, Cohen N, Cotter G, et al. Effects of captopril and enalapril on zincmetabolism in hypertensive patients. J Am Coll Nutr 1998;17:75-8.
144. Rubio-Luengo MA, Maldonado-Martin A, Gil-Extremera B, Gonzalez-Gomez L, Luna del Castillo JD. Variations in magnesium and zinc in hypertensive patients receiving different treatments. Am J Hypertens 1995;8:689-95.
145. Djordjevic VB, Grubor-Lajsic G, Jovanovic-Galovic A, Pavlovic D, Cvetkovic T, Pejovic M, et al. Selenium-dependent GSH-Px in erythrocytes of patients with hypertension treated with ACE inhibitors. J Environ Pathol Toxicol Oncol 1998;17:277-80.
146. Chel VG, Ooms ME, Popp-Snijders C, Pavel S, Schothorst AA, Meulemans CC, et al. Ultraviolet irradiation corrects vitamin D deficiency and suppresses secondary hyperparathyroidism in the elderly. J Bone Miner Res 1998;13:1238-42.